S&P Global enters its Q2 earnings window with a notable divergence: the stock just posted its best weekly gain in months, yet every major Wall Street firm covering it cut its price target within the past 48 hours.
The analyst action this week is the story. Five firms — JP Morgan, Barclays, Morgan Stanley, UBS, and RBC Capital — all trimmed their targets on July 7-8, yet every single one held a bullish rating. Morgan Stanley's Toni Kaplan cut from $557 to $525 while staying Overweight. JP Morgan's Andrew Steinerman followed with a reduction from $550 to $535, also Overweight. The sole outlier was BMO Capital, which actually nudged its target up to $505. The direction of travel is uniform: the Street remains constructive on SPGI's long-term franchise but is resetting near-term expectations lower ahead of the July 28 print. The consensus mean target now stands at $506 — a 14% premium to the current $443.46 — with the bear case centred on AI disruption fears weighing on Market Intelligence margins rather than any fundamental crack in the ratings or data businesses.
Options positioning adds a fresh wrinkle to that bullish-but-cautious analyst tone. The put/call ratio has fallen to 0.47, more than one standard deviation below its 20-day average of 0.67 — a notably call-skewed reading. One week ago this note flagged a similarly bullish options tilt at a PCR of 0.69; the ratio has shifted even further toward calls since then, even as the stock rallied 8.9% on the week to $443.46. That combination — rising stock plus a put/call ratio pressing toward the lower end of its annual range — points to options traders adding directional call exposure into strength rather than taking chips off the table.
The lending market tells a straightforwardly uncrowded story. Borrow availability remains effectively unlimited, with hundreds of millions of shares available relative to the modest short base. Cost to borrow has jumped from around 0.52% a week ago to 1.15% — roughly doubling — but in absolute terms that remains firmly in general-collateral territory with no squeeze dynamics. Short interest has climbed 10% over the past week and 30% over the past month to reach 1.75% of the free float, a move that sounds dramatic in percentage terms but leaves the actual positioning level low. The ORTEX short score of 31.2 sits in the lower third of its historical range, consistent with a stock where short sellers are nibbling but not crowding in. Factor scores corroborate this: analyst recommendation differential ranks in the 93rd percentile across the universe, while the dividend score hits 92nd — signals that long-side conviction remains high despite the target trims.
One institutional angle worth noting is the insider cluster from late April and early May. President and CEO Martina Cheung purchased roughly $998,000 of stock on April 29 at $429.93, while divisional CEO Cathy Clay added another $1.08 million on May 1 at $431.39. The stock now trades about 3% above those purchase prices. Net insider activity over the 90-day window ending May 1 was a positive $12.7 million — not a massive number for a company of this size, but the C-suite buying at levels below the current price provides a modest floor narrative heading into earnings.
Peer performance reinforces the sector-wide recovery that carried SPGI higher this week. Closest peer MCO gained 10.5% on the week, MSCI rose 9.0%, and FactSet added 10.6% — a broad re-rating of the financial data and analytics group rather than an SPGI-specific move. SPGI's 8.9% gain slightly lagged the peer average, meaning the target trims may have already introduced some modest valuation drag relative to the group.
With Q2 results due July 28, the key tension is whether Market Intelligence revenue and margins show the AI-disruption pressure that drove the target reductions, or whether the ratings and commodity businesses provide enough offset to sustain the Street's constructive stance despite lower price targets.
See the live data behind this article on ORTEX.
Open SPGI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
